

Gout: Diagnosis and Management Committee meeting 1

Date: 17/09/2020

Location: Video-conference via Zoom

Minutes: Final

Committee members present:		
Aung Soe		(Present for notes 1 – 4)
Ed Roddy		(Present for notes 1 – 4)
Alastair Dickson		(Present for notes 1 – 4)
Sam Finnikin		(Present for notes 1 – 4)
Hugh Gallagher		(Present for notes 1 – 4)
Kelsey Jordan		(Present for notes 1 – 4)
Mohammed Irfaniq		(Present for notes 1 – 4)
Jane Taylor		(Present for notes 1 – 4)

In attendance:		
Clifford Middleton	Guideline Commissioning Manager, NICE	(Present for notes 1 – 4)
Amber Hernaman	Project Manager, NGC	(Present for notes 1 – 4)
Sedina Lewis	Senior Research Fellow, NGC	(Present for notes 1 – 4)
Joseph Runicles	Information Specialist, NGC	(Present for notes 1 – 4)
Gill Ritchie	Guideline Lead, NGC	(Present for notes 1 – 4)
Audrius Stonkus	Research Fellow, NGC	(Present for notes 1 – 4)

4.0.03 DOC Cmte minutes

Alexandra Bonnon	Health Economist, NGC	(Present for notes 1 – 4)
------------------	-----------------------	---------------------------

Apologies:

Sarah Ryan	Committee member
Ben Williams-Shaw	Lay member
Sophia Kemmis Betty	Senior Health Economist, NGC

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the first guideline committee meeting on gout. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was

- Managing flares pharmacological and non-pharmacological interventions (protocol 3.1+3.2)
- Prevention of gout flares (protocol 4.5)

The Chair asked everyone to verbally declare any interests.

Name	Job title, organisation	Declarations of Interest	Type of interest	Decision taken
Alastair Dickson	Locum GP, York	Article on gout published in Daily Mail 31st August (online) and 1st September (in print) 2020:	Direct non-financial professional and personal	No action needed other than process of open declaration
Ed Roddy	Reader in Rheumatology and Honorary Consultant	Chief Investigator on a NIHR-RfPB funded observational study of the safety of colchicine and NSAID prophylaxis when	Direct non-financial professional and personal	No action needed other than process of

4.0.03 DOC Cmte minutes

	Rheumatologist, Keele University	initiating urate-lowering therapy for gout and prognostic factors for adverse events. Started Jan 2020		open declaration
		Co-investigator on a NIHR HTA-funded randomised trial of the clinical and cost-effectiveness of using a goal-directed allopurinol-based treat-to-target (T2T) protocol in people with recurrent gout attacks (flares). Started 2018-ongoing	Direct non-financial professional and personal	No action needed other than process of open declaration
		Co-investigator on a NIHR RfPB-funded feasibility study for a randomised trial of anakinra versus intramuscular methylprednisolone for acute gout attacks (flares) in patients with chronic kidney disease (ASGARD). Started 2017-ongoing	Direct non-financial professional and personal	No action needed other than process of open declaration
		Co-investigator of a Haywood Foundation (a local charity) funded study of the feasibility of a clinical laboratory delivered service for blood test monitoring in patients with gout. Started 2019-ongoing	Direct non-financial professional and personal	No action needed other than process of open declaration

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Presentations, questions and discussion

- a) Ed Roddy presented the guideline scope to the committee.
- b) Sedina Lewis presented and led discussion on minimum important difference and protocol development.

4.0.03 DOC Cmte minutes

c) The committee discussed and agreed the draft protocol for question:

3.1-3.2 what is the clinical and cost effectiveness of pharmacological and non-pharmacological interventions for managing gout flares?

4.5 what is the clinical and cost effectiveness of pharmacological prevention of flares during initiation or titration of ULT.

4. Any other business

None.

Date of next meeting: 18/09/20

Location of next meeting: Video-conference